

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/644,576
				Filing Date	August 20, 2003
				First Named Inventor	Connie Sanchez
				Art Unit	N/A
Examiner Name	Not Yet Assigned				
Attorney Docket Number	05432/100M919-US5				
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (# known)			
✓	AA**	US-2002/0040153-A1	04-04-2003	Petersen	
	AB**	US-6,258,842-B1	07-10-2001	Petersen et al.	
	AC**	US-6,365,747-B1	02-02-2002	Dall'Asta et al.	
	AD**	US-2004/0132808-A1	07-08-2004	Petersen et al.	
	AE**	US-5,627,196-A	05-06-1997	Hibschman et al.	


** Pursuant to the Notice issued by the United States Patent and Trademark Office dated July 11, 2003 waiving the requirements of 37 C.F.R. § 1.98(a)(2)(i), a copy/copies of the United States Patent on PTO/SB08 is/are not being submitted.

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)				
✓	1	WO-01/43525-A2	06-21-2001	Rock et al.		
	2	WO-99/14207-A1	03-25-1999	Berg Stefan		
	3	WO-0 814 084-A1	12-29-1997	Eli Lilly Co.		
	4	WO-96/24353-A1	08-15-1996	Eli Lilly Co.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
YK	5	AUQUIER, P., et al., Int. J. Psychiatr. Clin. Pract., 2003, Vol. 7, pp. 259-268.			
	6	BEIN, E., et al., Behav. Pharmacol., 2003, Vol. 14, p. S37.			
	7	FISH, E.W., et al., J. Pharmacol. Exp. Ther., October 30, 2003, Fast Forward publ. as DOI: 10.1124/jpet.103.058206, 2004.			
	8	SANCHEZ, Connie, et al., Psychopharmacology, 2003, Vol. 167, pp. 353-362.			
	9	SANCHEZ, Connie, et al., Behav. Pharmacol., 2003, Vol. 14, pp. 465-470.			
	10	SANCHEZ, Connie, et al., "Escitalopram versus citalopram: the surprising role of the R-enantiomer", Phsychopharmacology (Berl.), 2004.			
	11	HYTTEL, J., et al., "The pharmacological effect of citalopram resides in the (S) - (+)-enantiomer", Journal of Neural Transmission, 1992, Vol. 88, No. 2, pp. 157-160.			
	12	SANCHEZ, Connie, et al., "Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression", Psychopharmacology, 1997, Vol. 129, pp. 197-205.			
	13	LEPOLA, U., et al., "Citalopram in the Treatment of Social Phobia: A Report of Three Cases", Pharmacopsychiatry, September 1994, Vol. 27, No. 5, pp. 186-188.			
	14	HUMBLE, M., et al., "Serotonin, Panic Disorder and Agoraphobia: Short-Term and Long-Term Efficacy of Citalopram in Panic Disorders", International Clinical Psychopharmacology, 1992, Vol. 6, No. Suppl. 5, pp. 21-39.			

Examiner Signature		Date Considered	2/2/06
-----------------------	--	--------------------	--------



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/644,576
				Filing Date	August 20, 2003
				First Named Inventor	Connie Sanchez
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	05432/100M919-US5

✓	15	BOUWER, C., et al., "Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia", Journal of Affective Disorders, April 1998, Vol. 49, No. 1, pp. 79-82.	
---	----	--	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	2/2/06
-----------------------	--	--------------------	--------